CV-16

N/A

Report date: 2022/12/26 15:26:41

Base Information

Drug NameCV-16
Drug Alias NameCV-16CP-scFV KRAS
ClassificationBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionV-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog inhibitors
TargetsGTPase KRas
Therapy Area/IndicationsLung Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCellivery Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesCellivery Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsLung Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A